Escend Pharmaceuticals to Present Data Demonstrating Efficacy of ES-3000 in Models of Leukemic Stem Cells

Menlo Park, CA -- Escend Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of small molecule drug candidates for oncology orphan diseases, has been invited to present data on their lead compound, ES-3000, at the American Society of Hematology 58th Annual Meeting in San Diego, which takes place from December 2-6, 2016.

On December 3, 2016, at Poster Session 1 which takes place from 5:30-7:30 pm, Escend and its collaborators from the University of Massachusetts Medical School will present an abstract entitled “Inhibition of CML Stem Cells with an Alkaloid that Reduces β-catenin”. Data from both an in vivo murine model of CML stem cells and a colony forming cell (CFC) assay using bone marrow cells from a patient with CML will be presented.

About ES-3000

ES-3000 is an orally bioavailable small molecule which ablates leukemic stem cells by reducing β-catenin expression through a novel mechanism of action. Wnt/β-catenin pathway is critical for the survival of cancer stem cells.  ES-3000 is also in development for the treatment of acute myeloid leukemia (AML) and triple negative breast cancer (TNBC). ES-3000 has recently been granted an orphan designation from the U.S. FDA Office of Orphan Products for the treatment of CML.

About CML

In 2016, approximately 8,220 new cases of CML are expected to be diagnosed in the United States. Although CML is responsive to TKIs, such as imatinib, MRD remains a significant problem limiting long term control of disease, mostly due to the persistence of leukemic stem cells.  In addition, up to 33% of the TKI treated patients will not attain optimal responses, calling for the development of additional therapies addressing minimal residual disease. Currently, there are no FDA approved anti-leukemic stem cell therapies.

About Escend Pharmaceuticals, Inc.

Escend Pharmaceuticals’ mission is to develop therapeutics for oncology orphan indications by ablating cancer stem cells. Our business strategy is to select small molecule drug candidates with established clinical safety that have not yet achieved US marketing approval and match them to appropriate oncology indications, where their effects on specific cellular pathways can be exploited for the development of novel therapeutics. For further information, please visit